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Precis for use in the Table of Contents: In recurrent/metastatic HNSCC, tivantinib + 
cetuximab did not significantly improve tumor response rate or overall survival compared to 
cetuximab alone but increased toxicity. HPV/p16-positive patients had a 0% response rate within 
the study, consistent with other reports that EGFR inhibitors appear to be less active in HPV/p16 
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Abstract:
Background: MET signaling is a well-described mechanism of resistance to anti-EGFR therapy, 
and MET over-expression is common in head and neck squamous cell carcinomas (HNSCC). 
This trial compared the oral MET inhibitor tivantinib (ARQ197) in combination with cetuximab 
(TC) versus cetuximab monotherapy (C) in patients with recurrent/metastatic HNSCC. 
Patients and methods: 78 evaluable cetuximab-naïve platinum-refractory HNSCC patients were 
enrolled, 40 on the TC arm, and 38 on the cetuximab control arm (stratified by HPV-status). 
Tivantinib was given orally 360mg twice a day, cetuximab 500mg/m2 iv biweekly. Primary 
outcome was response rate (RECIST 1.1), secondary outcomes included progression free and 
overall survival (PFS, OS). After progression on the control arm, tivantinib monotherapy was 
optional. 
Results: The response rate in the TC arm was 7.5% (N=3, one CR), and 7.9% (N=3) in the C 
arm (NS). Median PFS in both arms was 4 months (NS), median OS 8 months (NS). Both 
treatments were well tolerated with a trend towards increased hematological toxicities in the TC 
arm (12.5% with grade 3 leukopenia). Response rate in 31 HPV/p16-positive pts was 0% in both 
arms, while the response rate in HPV-negative pts was 12.7% (12.5%(TC), 13%(C)). Fifteen 
patients received tivantinib monotherapy, no responses were observed. 
Conclusions: Tivantinib + cetuximab does not significantly improve response rate or survival 
compared to cetuximab alone, but increases toxicity in an unselected HNSCC population. 
Cetuximab responses appear limited to HPV-negative HNSCC patients. MET-aberration focused 
trials for HNSCC, and use of higher-potency, selective MET inhibitors remain of interest. 
Keywords: head and neck squamous cell carcinoma, c-MET, tivantinib, cetuximab, recurrent 
disease, metastatic disease
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Introduction:
The prognosis of patients with recurrent or metastatic head and neck squamous cell 
carcinoma (HNSCC) after failure of first-line platinum containing chemotherapy remains poor 
with an estimated survival of 6-8 months[1]. In platinum-refractory patients, options are limited 
and include cytotoxic chemotherapy, anti-EGFR therapy with cetuximab, and since 2016, 
immune checkpoint inhibition[2]. Objective responses to cytotoxic chemotherapy are generally 
≤10% after failure of first-line therapy. While checkpoint inhibition alone or in combination with 
chemotherapy is active, objective response rates are modest ranging from 13.3-18%[3]. Thus, 
optimizing targeted therapy approaches remains of interest.
Epidermal growth factor receptor (EGFR) is expressed at high levels in a majority of 
head and neck cancers and expression is associated with poor prognosis[4]. Treatment with the 
anti-EGFR antibody cetuximab (alone or in combination with chemotherapy) is approved in the 
United States for patients with recurrent/metastatic disease[1, 5, 6]. Despite frequent expression 
in HNSCC, the objective response rate to cetuximab monotherapy is only 10-13%[5], and 36% 
in combination with chemotherapy[1]. Given the modest clinical activity, investigation of 
combination approaches that target escape signaling pathways has been of interest[7, 8] in order 
to improve efficacy.
The MET receptor tyrosine kinase is overexpressed in HNSCC[9]. Preclinical data in 
HNSCC support co-targeting of EGFR and MET and reveal synergy in models with extensive 
signaling crosstalk[10, 11]. 
Tivantinib (ARQ 197), is an oral, non-competitive MET inhibitor that has shown anti-
tumor efficacy in several diseases[12]. Tivantinib has broad spectrum anti-tumor activity both as 
a single agent and in combination in preclinical studies in HNSCC cell lines[13, 14]. Clinical 
studies of tivantinib combined with EGFR inhibition have been well tolerated[15]. 
Given the frequency and targetability of MET in HNSCC, the active and well-tolerated 
toxicity profile of tivantinib, and the documented synergy of EGFR and MET in HNSCC 
preclinical models, we proposed to study the EGFR inhibitor cetuximab and the MET inhibitor 
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Patients enrolled were ≥18 years of age with histologically or cytologically confirmed 
HNSCC not amenable to curative intent therapy. Both HPV-positive (HPV+) and HPV-negative 
(HPV-) patients were eligible, with HPV status determination required prior to enrollment. 
Patients were required to have measurable disease as per Response Evaluation Criteria in Solid 
Tumors (RECIST v1.1), Eastern Cooperative Group Performance Status (ECOG) 0-1, normal 
organ and marrow function, a life expectancy of greater than 8 weeks, the ability to swallow pills 
and no active cardiac disease (such as history of congestive heart failure, active coronary artery 
disease, uncontrolled cardiac arrhythmia, uncontrolled hypertension, myocardial infarction 
within 6 months of enrollment). Patients who received treatment with an EGFR inhibitor in the 
curative intent setting remained eligible, but patients who were treated in the palliative intent 
setting with an EGFR or MET inhibitor or who received more than 2 palliative cytotoxic 
treatments were ineligible. Patients with active brain metastases, pregnancy, comorbidities 
interfering with therapy or survival, or other malignancies within 3 years were excluded. Written 
informed consent was obtained from every patient prior to enrollment. Patients were enrolled 
across 16 institutions, a full list available on www.clinicaltrials.gov (Clinical Trials.gov 
Identifier: NCT01696955).  
Investigational treatment
Prior to treatment, patients underwent cross-sectional imaging, laboratory evaluation, 
electrocardiogram, and full physical examination. Patients were randomized 1:1 using the 
method of permuted blocks, and stratified by HPV status. Any commonly used HPV test (e.g. 
p16 IHC, ISH etc.) was acceptable; in the case of discrepancies between p16 & ISH, the ISH 
result was used. Any HPV(+) by p16 alone, regardless of primary site, was assigned to the HPV+ 
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tablet self-administered orally twice daily. Patients who progressed on the cetuximab-only arm 
had the option to receive tivantinib single agent therapy (orally BID on days 1-28) afterwards. 
Cycle length was 4 weeks, and imaging occurred every 8 weeks. 
Endpoints and Statistical Methods
The primary endpoint was objective response rate (ORR), defined as the percentage of 
patients whose best response from baseline to nadir was either a complete (CR) or partial 
response (PR), according to RECIST v1.1. All randomized patients who received study drug 
were included in response rate analysis; patients who did not undergo a first imaging evaluation 
for any reason were counted as non-responders. ORRs between the two arms were compared 
using Fisher’s exact test. Statistical power calculations indicated that a sample size of N=38 
patients per arm would achieve 80% power to detect a difference of 12% versus 35% between 
the cetuximab and combination treatment arms, using a one-sided test at the alpha=0.10 
significance level. 
Secondary endpoints included PFS, OS, tumor shrinkage at 8 weeks, and single agent 
activity of tivantinib after failure of cetuximab (descriptive). PFS was defined as time from 
randomization until disease progression, death from any cause, or date last known as 
progression-free; OS was the time from randomization until death or date last known alive. 
Kaplan-Meier curves were generated for PFS and OS and the treatment arms were compared via 
logrank tests. Tumor shrinkage at 8 weeks was compared using a two-sample t-test. Single agent 
activity of tivantinib was described by the ORR and adverse event profiles of patients who 
received tivantinib monotherapy. 
All toxicities were graded according to the US National Cancer Institute Common 
Toxicity Criteria (version 4.0). Adverse events reported in arm C were prior to any crossover to 
tivantinib monotherapy. 
Results:
81 patients were enrolled from 2012 until 2014, and 78 patients started treatment (N=78) 
(Table 1, Figure 1). 40 patients were randomized to the tivantinib + cetuximab (TC) arm, and 38 
randomized to the cetuximab (C) arm. Of the 81 enrolled patients, three never received study 















This article is protected by copyright. All rights reserved
insurance denial, one withdrew consent prior to starting). Among 78 patients who received 
treatment 11 patients (TC, N=7; C, N=4) came off treatment for an adverse event, death, 
withdrawal, or crossover prior to first evaluation, and were included in the primary outcome 
analysis as non-responders.
After progression on the cetuximab control arm, fifteen patients went on to receive 
single-agent tivantinib. Patient characteristics are shown in Table 1 and are similar between both 
treatment arms. Patients enrolled were primarily male (TC: 85.0%, C: 84.2%), with ages ranging 
from 35-90. Sixteen patients (40.0%) were HPV(+) on the TC arm, and fifteen (39.5%) were 
HPV(+) on the C arm. 70.0% of patients on the TC arm had ≥ 2 prior therapies, compared to 
81.6% of patients on the C arm (NS).
Response - Primary Endpoint
Response rate was not significantly different between the two arms (Table 2): 7.5% (3/40 
responses) on the TC arm and 7.9% (3/38 responses) on the cetuximab arm (P=1.0). On the TC 
arm, two patients had a partial response and one patient had a complete response (CR=2.5%; 
PR=5.0%); on the cetuximab arm three patients had a partial response (PR=7.9%). For patients 
undergoing at least one imaging assessment, response of target lesions from baseline to nadir is 
described in the waterfall plot in Figure 2a. The most common reason for treatment 
discontinuation was progressive disease (N=48, 61.5%), followed by adverse events (N=11, 
14.1%), study withdrawal (N=6, 7.7%), and death (N=6, 7.7%).
In a post-hoc subgroup analysis, the response rate in 31 HPV(+)/p16-positive HNSCC pts 
was 0% in both arms. The response rate in HPV(-) patients was 12.7% (TC:12.5%, C:13%).
Secondary Endpoints – Single agent Tivantinib activity
Patients on the cetuximab (C) control arm had the option to receive single agent 
tivantinib upon progression: 15 out of 38 patients received tivantinib alone.  None of these 
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Secondary Endpoints – Tumor shrinkage at 8 weeks
For the TC arm, the mean shrinkage was a 15.0% increase (N=32, SD 34.7%); for the C 
arm, the mean change was a 9.0% increase (N=31, SD 30.8%) (P=0.47). Waterfall plots are 
shown in Figure 2b. 
Secondary Endpoints – Progression Free and Overall Survival 
For the TC arm, median PFS was 3.5 months (95% CI [1.8-3.9]); for the C arm, median 
PFS was 3.5 months (95% CI [2.0-3.9])(Figure 3a) (logrank P=0.99). For the TC arm, median 
OS was 7.4 months (95% CI [4.7-10.3]); for the C arm, OS was 8.6 months (95% CI [5.7-
11.5])(Figure 3b) (logrank P=0.58). 
All-cause mortality rate while on study was 36/40 (90%) on the TC arm and 35/38 
(92.1%) on the C arm. 
Toxicity
All 78 patients treated were evaluable for safety assessments. The most common grade 
≥3 adverse events (AEs) (occurring>1 patient) attributed as at least possibly related to study drug 
for both treatment arms are presented in Table 3. There were a total of 84 grade ≥3 AEs reported 
on the TC arm among the 40 patients (N=43 at least possibly related), and 53 on the C arm 
(N=23 at least possibly related). Myelosuppression was observed on the TC combination arm 
only: Grade ≥3+ myelosuppression occurred in 18/40 patients (45%), compared to 3/38 (7.9%) 
for the C arm.
There were two grade 5 AEs/deaths attributed as possibly related to study drug: 
pneumonia/lung infection (TC), and one septic death while on tivantinib monotherapy. The 
patient on the TC arm was hospitalized with lung infection in the setting of febrile neutropenia 
15 days after the first treatment with cetuximab and tivantinib; the patient’s condition 
deteriorated and they died two weeks later. The patient who crossed over to tivantinib 
monotherapy from the C arm was admitted with severe hypoxia and persistent neutropenia, 
which worsened to hypoxic respiratory failure in the setting of neutropenic fever and 
pseudomonas sepsis.
Of the fifteen patients who went on to receive single-agent tivantinib, 4/15 (26.7%) 
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(≥15%) were anemia, fatigue, decreased lymphocyte count, hypomagnesemia, and hypertension, 
each of which were reported in 3/15 patients (20%).
Discussion:
A randomized, multicenter study was performed to evaluate the role of adding the MET 
small molecular inhibitor tivantinib to anti-EGFR therapy with cetuximab based on preclinical 
data [10, 11] and data in other cancer types (NSCLC[16, 17]) that MET inhibition synergizes 
with anti-EGFR therapy. However, this was a negative trial. The addition of tivantinib did not 
improve tumor response rate nor overall survival outcomes compared to cetuximab monotherapy 
in an unselected population of patients with recurrent/metastatic HNSCC. Furthermore, there 
was no single agent activity with tivantinib after cetuximab, although treatment was optional and 
hence may be subject to a selection bias. Importantly, toxicity from tivantinib was prominent in 
particular in the form of myelotoxicity with 45% of patients on the TC arm experiencing grade 
≥3 myelotoxicity (compared to 7.9% on the cetuximab arm). In addition, two possibly tivantinib-
related grade 5 events occurred (1 on TC arm, and 1 on tivantinib monotherapy). Toxicities 
typical for other selective MET or HGF inhibitors, e.g. ankle edema or renal toxicity were not 
observed. Henceforth, further development of tivantinib for HNSCC should not be pursued.
Interestingly, in a post-hoc exploratory subgroup analysis, we show a 0% ORR in 
HPV(+) patients on both arms, compared to 12.5% (TC)/ 13.0% (C) in HPV(-) patients, driven 
by cetuximab therapy[18]. These results are consistent with other reports that EGFR inhibitors, 
including cetuximab, appear to be less active in HPV/p16 positive HNSCC patients[6, 19, 20]. 
Comprehensive genomic analysis has revealed that EGFR gene amplification is common in 
HPV(-) HNSCC, whereas almost non-existent in HPV(+) HNSCC[9, 18, 21]. This evidence 
suggests that HPV(+) HNSCC may not be a suitable population for anti-EGFR therapies.  
Tivantinib may not be an ideal MET inhibitor. Tivantinib’s mechanism of action as a 
non-competitive inhibitor is not fully understood: While its ability to bind and inhibit MET is 
well known and modest, tivantinib has also shown cytotoxic effects (i.e. tubulin binding) 
reminiscent of a spindle poison [22] and likely accounts for the myelotoxicity and lack of MET 
specific toxicities such as edema and renal toxicity[23, 24]. Tivantinib appears less selective than 
other MET inhibitors: its effects have been seen in the absence of MET expression and in 
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not show activity, in contrast to prior activity with foretinib, a dual MET/VEGFR inhibitor, in a 
similar population [26]. 
This study was performed in an unselected population, and no post-hoc MET expression 
analysis was pursued due to low response rates. A recent meta-analysis of tivantinib in solid 
tumor types (not including HNSCC) showed significant improvement in PFS & OS in the MET-
high subgroup but not the unselected population[15]. Selection for high-MET expressing 
HNSCC could be considered in the future. 
Newer, more specific, higher potency MET inhibitors are currently being developed for 
use in MET exon14 skipping and higher-level MET amplified NSCLC with early promising 
data[24, 27]. Both exon 14 skipping and MET amplification have been reported in HNSCC, and 
while uncommon[9], they might provide a more selective way forward to investigate MET or 
dual MET/EGFR inhibition in HNSCC. 
In conclusion, tivantinib + cetuximab did not significantly improve tumor response rate 
or overall survival compared to cetuximab alone but increased toxicity. No single agent 
tivantinib activity was witnessed. Given these results, further development of tivantinib in 
HNSCC should not be pursued. Cetuximab responses appeared to be limited to HPV(-) HNSCC 
patients, consistent with reports that EGFR inhibitors may be less effective in HPV(+) HNSCC. 
Future MET-aberration-focused trials should include HNSCC patients, and use of higher-
potency, selective MET inhibitors remain of interest.
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Figure 1. 
Trial Schema and patient allocation.
Figure 2. 
Waterfall plots for (a) best response from baseline to nadir and (b) early tumor shrinkage from 
baseline to week 8, measured by Response Evaluation Criteria In Solid Tumors (RECIST v1.1), 
for each arm. 
Figure 3. 
Kaplan-Meier survival curves for (a) median overall survival and (b) median progression-free 
survival for each arm. TC is the tivantinib + cetuximab arm (in blue), C is the cetuximab 
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Tables: 
 
Table 1. Clinical Patient Characteristics by Treatment Arm 
 No. of Patients (%) 





Mean age (range) 60.5 (37-90) 63.6 (35-87) 
Male 34 (85.0) 32 (84.2) 
HPVa Status   
Positive 16 (40.0) 15 (39.5) 
Negative 24 (60.0) 23 (60.5) 
Race   
White 31 (77.5) 32 (84.2)  
African American 4 (10.0) 3 (7.9) 
Hispanic 1 (2.5) 1 (2.6) 
Asian 3 (7.5) 2 (5.3) 
Unknown 1 (2.5) 0 (0.0) 
Number of Prior Therapies   
0 9 (22.5) 5 (13.2) 
1 3 (7.5) 2 (5.3) 
2 12 (30.0) 10 (26.3) 
3 3 (7.5) 6 (15.8) 
4 5 (12.5) 4 (10.5) 
5 3 (7.5) 6 (15.8) 
6 or more 5 (12.5) 5 (13.2) 
ECOGb Performance Status   
Normal activity, asymptomatic 17 (42.5) 19 (50.0) 
Symptomatic, fully ambulatory 23 (57.5) 19 (50.0) 
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Table 2. Best Response by Treatment Arm (Primary Endpoint) 
 
 No. of Patients (%) 







Complete 1 (2.5) 0 (0.0) 
Partial 2 (5.0) 3 (7.9) 
Stable disease 15 (37.5) 12 (31.6) 
Progressive disease 15 (37.5) 19 (50.0) 
Off treatment for AEa < 1st 
evaluation 
3 (7.5) 2 (5.3) 
Death < 1st evaluation 2 (5.0) 0 (0.0) 
Withdrew < 1st evaluation 2 (5.0) 1 (2.6) 
Crossover < 1st evaluation 0 (0.0) 1 (2.6) 
Objective Response Rate 3/40 = 7.5% 3/38 = 7.9% 
aAE, adverse event.  
 
 
Table 3. Summary of Frequent Adverse Events Deemed At Least Possibly Relateda 
 No. of Patients (%) 




Grade Any 3+ Any 3+ 
Hematologic AEsb     
Anemia  12 (30) 2 (5) 4 (10.5) 1 (2.6) 
Lymphocyte count decreased  6 (15) 4 (10) 1 (2.6) 1 (2.6) 
Neutrophil count decreased  9 (22.5) 5 (12.5) 1 (2.6) 0 
Platelet count decreased  6 (15) 0 1 (2.6) 0 
White blood cell decreased  9 (22.5) 5 (12.5) 3 (7.8) 1 (2.6) 
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Anorexia  9 (22.5) 0 5 (13.2) 0 
Fatigue  18 (45) 3 (7.5) 14 (37) 0 
Hypomagnesemia  6 (15) 0 10 (26) 4 (10.5) 
Nausea  9 (22.5) 1 (2.5) 6 (15.8) 0 
Rash acneiform  19 (47.5) 2 (5) 19 (50.0) 2 (5.3) 
Rash maculo-papular  10 (25) 1 (2.5) 9 (23.7) 0 
Rash/dermatitis  6 (15) 0 8 (21.0) 0 
Sinus bradycardia  6 (15) 0 1 (2.6) 1 (2.6) 
Stomatitis/pharyngitis  8 (20) 3 (7.5) 5 (13.2) 0 
Vomiting  6 (15) 1 (2.5) 3 (7.8) 0 
aFrequency cutoff for grade 1-2 AEs is 15%, and grade 3+ occurring in >1 patient/s for either arm. 
Maximum grade per patient reported.  
bAE, adverse event.  
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